Get the Stockscreener App
27.44
0.81%
0.22
Pre-market:
27.60
0.16
+0.58%
Beam Therapeutics Inc stock is traded at $27.44, with a volume of 2.22M.
It is up +0.81% in the last 24 hours and up +1.82% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
See More
Previous Close:
$27.22
Open:
$27.775
24h Volume:
2.22M
Relative Volume:
1.23
Market Cap:
$2.79B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-15.16
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
-7.33%
1M Performance:
+1.82%
6M Performance:
+48.00%
1Y Performance:
+3.78%
1-Day Range:
$26.66
$28.26
1-Week Range:
$26.66
$29.63
52-Week Range:
$13.53
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
27.44 | 2.77B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Canaccord Genuity | Buy |
| Oct-09-25 | Initiated | Jefferies | Buy |
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
ARK Investment Boosts Stake in Beam Therapeutics - National Today
Amova Asset Management Americas Inc. Buys 103,939 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Earnings Call Highlights PKU Pivot - TipRanks
What is HC Wainwright's Forecast for BEAM Q1 Earnings? - MarketBeat
Mintz Advises Sixth Street On $500 Million Strategic Financing Facility With Beam Therapeutics - Mondaq
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) - ADVFN Ltd
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com UK
Contrarius Group Holdings Ltd Buys Shares of 1,533,269 Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vanguard Group Inc. Sells 455,440 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM SEC FilingsBeam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
BEAM.O PE Ratio & Valuation, Is BEAM.O Overvalued - Intellectia AI
RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here’s Why - Yahoo Finance
Beam Therapeutics (NASDAQ:BEAM) Raised to Hold at Wall Street Zen - MarketBeat
BEAM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Should You Buy Beam Therapeutics Inc (BEAM) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Assessing Beam Therapeutics (BEAM) Valuation After Q4 Earnings Surprise Credit Facility And PKU Program Launch - simplywall.st
Beam Therapeutics: Great Potential, But Patience Is Needed (NASDAQ:BEAM) - Seeking Alpha
Beam Therapeutics reveals new program for PKU - bioworld.com
Bernstein SocGen cuts Beam Therapeutics stock price target on valuation By Investing.com - Investing.com Canada
Bernstein SocGen cuts Beam Therapeutics stock price target on valuation - Investing.com
Beam Therapeutics Clarifies Growth Path With PKU Program And New Financing - Yahoo Finance
Beam Therapeutics (BEAM) Quarterly Profit Surprises Loss Narrative With US$244.3 Million Net Income - simplywall.st
Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.3%Time to Sell? - MarketBeat
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street - WilmerHale
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y - Finviz
Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $26.00 - MarketBeat
BEAM Shares See Target Price Boost by RBC Capital | BEAM Stock N - GuruFocus
Beam Therapeutics Stock Surges 14% on Strategic Financing: How the $500M Agreement Secures a $156 Target - TIKR.com
Beam Therapeutics Opens with 7.83% Gain, Outperforming S&P 500's 0.69% Rise - Markets Mojo
Beam Therapeutics Hits Day High with 17.04% Surge in Stock Price - Markets Mojo
Wedbush Raises BEAM Price Target to $65, Maintains Outperform Ra - GuruFocus
Beam Therapeutics (NASDAQ:BEAM) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Beam Therapeutics (BEAM) stock edges up premarket after 14% jump on results, $500 million facility - Bez Kabli
RBC Capital Adjusts Beam Therapeutics Price Target to $26 From $22, Maintains Sector PerformSpeculative Risk Rating - marketscreener.com
Beam Therapeutics Inc. (NASDAQ:BEAM) Q4 2025 Earnings Call Transcript - Insider Monkey
Mintz Advises Sixth Street on $500 Million Strategic Financing Facility with Beam Therapeutics - Mintz
Decoding Beam Therapeutics Inc (BEAM): A Strategic SWOT Insight - GuruFocus
Beam Therapeutics Inc. (BEAM) Stock Analysis: Exploring a 72.96% Potential Upside in the Biotech Innovator - DirectorsTalk Interviews
Beam Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Earnings Call Summary | Beam Therapeutics(BEAM.US) Q4 2025 Earnings Conference - 富途牛牛
[144] Beam Therapeutics Inc. SEC Filing - Stock Titan
BofA raises Beam Therapeutics stock price target on pipeline progress By Investing.com - Investing.com Australia
Beam Therapeutics Inc (BEAM) Q4 2025 Earnings Call Highlights: Strategic Financing and ... By GuruFocus - Investing.com Canada
Beam Therapeutics Inc (BEAM) Q4 2025 Earnings Call Highlights: S - GuruFocus
What's Going On With Beam Therapeutics Stock?Beam Therapeutics (NASDAQ:BEAM) - Benzinga
BofA raises Beam Therapeutics stock price target on pipeline progress - Investing.com
Beam Therapeutics Shares Rise After Swinging to Q4 Adjusted Earnings - marketscreener.com
Analyst bullish on Beam Therapeutics (BEAM) over drug program trajectory - MSN
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):